Glioma targeted therapy: insight into future of molecular approaches
Gliomas are the common type of brain tumors originating from glial cells. Epidemiologically,
gliomas occur among all ages, more often seen in adults, which males are more susceptible …
gliomas occur among all ages, more often seen in adults, which males are more susceptible …
Revisiting platinum-based anticancer drugs to overcome gliomas
Although there are many patients with brain tumors worldwide, there are numerous
difficulties in overcoming brain tumors. Among brain tumors, glioblastoma, with a 5-year …
difficulties in overcoming brain tumors. Among brain tumors, glioblastoma, with a 5-year …
Integrated response analysis of pediatric low-grade gliomas during and after targeted therapy treatment
JW Tsai, JJ Choi, H Ouaalam, EA Murillo… - Neuro-Oncology …, 2023 - academic.oup.com
Background Pediatric low-grade gliomas (pLGGs) are the most common central nervous
system tumor in children, characterized by RAS/MAPK pathway driver alterations. Genomic …
system tumor in children, characterized by RAS/MAPK pathway driver alterations. Genomic …
Pediatric and adult low-grade gliomas: where do the differences lie?
L Greuter, R Guzman, J Soleman - Children, 2021 - mdpi.com
Two thirds of pediatric gliomas are classified as low-grade (LGG), while in adults only
around 20% of gliomas are low-grade. However, these tumors do not only differ in their …
around 20% of gliomas are low-grade. However, these tumors do not only differ in their …
[HTML][HTML] The mechanisms of current platinum anticancer drug resistance in the glioma
E Lu, I Gareev, C Yuan, Y Liang, J Sun… - Current …, 2022 - ncbi.nlm.nih.gov
Gliomas are the most common and malignant primary tumors of the central nervous system
(CNS). Glioblastomas are the most malignant and aggressive form of primary brain tumors …
(CNS). Glioblastomas are the most malignant and aggressive form of primary brain tumors …
Glioma-targeted oxaliplatin/ferritin clathrate reversing the immunosuppressive microenvironment through hijacking Fe2+ and boosting Fenton reaction
X Li, Y Cheng, Z Yang, Q Ji, M Huan, W Ye… - Journal of …, 2024 - Springer
Glioma is easy to develop resistance to temozolomide (TMZ). TMZ-resistant glioma secretes
interleukin-10 (IL-10) and transforming growth factor-β (TGF-β), recruiting regulatory T cell …
interleukin-10 (IL-10) and transforming growth factor-β (TGF-β), recruiting regulatory T cell …
Development of a novel glycolysis-related genes signature for isocitrate dehydrogenase 1-associated glioblastoma multiforme
X Cai, Z Chen, C Huang, J Shen, W Zeng… - Frontiers in …, 2022 - frontiersin.org
Background The significant difference in prognosis between IDH1 wild-type and IDH1
mutant glioblastoma multiforme (GBM) may be attributed to their metabolic discrepancies …
mutant glioblastoma multiforme (GBM) may be attributed to their metabolic discrepancies …
Radiotherapy for pediatric low-grade glioma
I Bansal, TE Merchant - Child's Nervous System, 2024 - Springer
Methods This review by Indu Bansal and Thomas E. Merchant examines the indications,
timing, and results of radiotherapy for pediatric low-grade glioma. The authors provide a …
timing, and results of radiotherapy for pediatric low-grade glioma. The authors provide a …
Prognostic role of BRAF mutation in low-grade Gliomas: meta-analysis
Z Kai, L Dingyang, Y Zhuanyi - World neurosurgery, 2021 - Elsevier
Objective Newly emerged molecular markers in gliomas provide prognostic values beyond
the capabilities of histologic classification. BRAF mutation, especially BRAF V600E, is …
the capabilities of histologic classification. BRAF mutation, especially BRAF V600E, is …
Thromboembolic toxicity observed with concurrent trametinib and lenalidomide therapy
PP Chan, A Sabus, MS Hemenway… - Pediatric blood & …, 2023 - Wiley Online Library
The event‐free survival of pediatric low‐grade gliomas is poor, and patients often require
multiple treatment strategies. While MEK and RAF inhibitors are efficacious in early‐phase …
multiple treatment strategies. While MEK and RAF inhibitors are efficacious in early‐phase …